Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 June 2022 | Story Prof Felicity Burt, Prof Dominique Goedhals and Dr Charles Kotzé
Prof Felicity Burt, Dr Charles Kotze and Prof Dominique Goedhals
From the left; Prof Felicity Burt, Dr Charles Kotzé and Prof Dominique Goedhals.

Opinion article by Prof Felicity Burt , Prof Dominique Goedhals , Division of Virology at the University of the Free State (UFS), and Dr Charles Kotzé, National Health Laboratory Service (NHLS), Universitas Academic Hospital.
The recent COVID-19 pandemic has certainly highlighted the importance of vigilance and awareness of emerging diseases with public health implications. The monkeypox virus has recently made headlines, after the detection of more than 200 cases in geographically distinct regions. On 13 May, the World Health Organisation (WHO) was notified of human cases of the monkeypox disease occurring in the United Kingdom, outside of the known endemic region.

Exported cases have been detected previously and usually occur sporadically. In contrast, within the past two weeks, human cases have been confirmed in at least 21 countries, including various European countries, the United Kingdom, Israel, the Canary Islands, Canada and the United States, and Australia. The initial case appears to have been a traveller from Nigeria. Sequence data may help to determine if there have been multiple exportations from West Africa. 

What is monkeypox and what do we know

What is monkeypox and what do we know about the aetiologic agent? Monkeypox is the name given to a disease caused by the monkeypox virus, a zoonotic pathogen endemic in Central and West Africa and responsible for cases of the disease in the endemic region, with occasional exported cases in travellers. The virus was initially identified in 1958 in monkeys housed at a research laboratory in Denmark, and the name monkeypox was derived from the appearance of lesions and the occurrence in monkeys. The first human case was identified 52 years ago in the Democratic Republic of the Congo. Since then, human monkeypox cases have been reported in several other Central and West African countries: Cameroon, the Central African Republic, Ivory Coast, the Democratic Republic of the Congo, Gabon, Liberia, Nigeria, Republic of the Congo, and Sierra Leone. The first monkeypox outbreak outside of Africa was in the United States of America in 2003 and was linked to contact with infected prairie dogs imported as exotic pets. Since then, there have been various small, contained outbreaks outside of Africa that have mostly been linked to the importation of the virus from African countries. 

The virus is related to the smallpox virus, which was eradicated in the 1970s by vaccination. Although belonging to the same family of viruses as the smallpox virus, the disease caused by monkeypox is less severe, with fewer fatalities.   Unlike smallpox, which carries a case fatality rate of 30%, the case fatality rate in monkeypox is low (estimated at 3-6% in more recent outbreaks).  There are two clades of the monkeypox virus: the West African clade and the Congo Basin (Central African) clade. In this outbreak, all of the cases have been linked to the West African clade of the monkeypox virus.

Transmission occurs from animal to human, and from human to human, through close contact with lesions, body fluids, and contaminated materials. The virus enters the body through the respiratory tract, mucous membranes, or broken skin.  The disease begins with non-specific symptoms such as fever, headache, muscle pains, and swollen lymph nodes. This is followed by the typical skin rash, which progresses through stages known as macules, then papules, vesicles, pustules, and lastly crusts or scabs. Lesions can also occur on mucous membranes such as the mouth, eye, and genital area.  The infectious period lasts through all stages of the rash, until all the scabs have fallen off. There are a number of other infectious and non-infectious conditions that need to be differentiated; therefore, individuals presenting with these symptoms will need to consult their doctor to determine whether a diagnosis of monkeypox needs to be considered. In the current outbreak, a number of the cases in the United Kingdom and Europe have been detected in men who have sex with men, during visits to sexual health clinics. This pattern of spread has not previously been described and it remains to be determined whether the spread has occurred through close person-to-person contact or through sexual transmission.  

Vaccination against smallpox virus offers 85% protection against monkeypox

To date, no cases have been detected in South Africa, but the recent global spread of the severe acute respiratory syndrome coronavirus 2 (SARS_CoV-2) highlights the ability of pathogens to spread. The National Institute for Communicable Diseases (NICD) in Johannesburg offers a specialised diagnostic service for the monkeypox virus, using molecular assays and electron microscopy. 

Vaccination against the smallpox virus is believed to offer 85% protection against monkeypox, hence older persons should have some protection; however, vaccination against smallpox was phased out globally following the eradication of smallpox during the 1970s. A more recently developed vaccine against monkeypox is available but has very limited availability.  No specific antivirals are available with proven efficacy in clinical trials.

While the monkeypox virus can be spread via the respiratory route, this occurs in the form of large droplets, rather than aerosol transmission, which is seen with SARS-CoV-2 (causing COVID-19). Aerosols are smaller particles that can remain suspended in the air for prolonged periods, facilitating the transmission of SARS-CoV-2. Monkeypox is therefore less contagious than COVID-19, as close contact is required for longer periods.  For this reason, many experts around the world predict that this outbreak will not spread like SARS-CoV-2. The importation of monkeypox to South Africa is a definite possibility, because South Africa is a significant economic and travel hub for Africa. Previous outbreaks of monkeypox in non-endemic areas have been interrupted by contact tracing and isolation, which was very effective in controlling further spread.  Heightened vigilance is therefore needed for the early detection of such cases.

News Archive

UFS Dean scoops prestigious award for analysis of book of Malachi
2017-05-15

Description: Prof Fanie Snyman book Tags: Prof Fanie Snyman book

Willem Louw, Chairperson of the UFS Council;
Dr Khotso Mokhele , Chancellor of the UFS,
Eleanor van der Westhuizen, from the Directorate
of Research Development; Prof Francis Petersen,
UFS Vice-Chancellor and Rector; Prof Fanie Snyman,
Dean of the Faculty of Theology; and
Prof Corli Witthuhn, Vice-Rector: Research.
Photo: Johan Roux

The most sought-after award at the UFS, the annual Book Prize for Distinguished Scholarship, was recently won by Prof Fanie Snyman, Dean of the Faculty of Theology and Religion. His book, Malachi, which is about the last book of the Old Testament, has received acknowledgement through this award. He is the third academic to be awarded this prize. The book was published in English by Peeters Publishers in Belgium as part of the ”Historical Commentary on the Old Testament” series with a view to an international audience, and can be used by theology scholars and academics.

Labour of love over many years
Prof Snyman has a long history with the Bible book of Malachi. Since his student years, this book in the so-called ‘Minor Prophets’ of the Old Testament had a special charm for him. In fact, Prof Snyman has produced several publications on this concise book of 55 verses over the years. Furthermore, his doctoral thesis, as well as several papers delivered at congresses, also had this book as the theme. It took Prof Snyman about a decade to write the book.

What lies ahead for him in the future? “I am closing the book Malachi for the time being,” says Prof Snyman. “However, my research on the ‘Minor Prophets’ will continue. As a result of Malachi, InterVarsity Press in Cambridge contacted me for the writing of a book in another international commentary series, this time on the books Nahum, Habakkuk, and Zephaniah.” Prof Snyman will use his prize money of R75 000 towards this goal.

Book prize a surprise
“I can sincerely say that I did not expect the award at all. I did not know which other excellent research was submitted and thought that research from another discipline might do better. Therefore, I was completely surprised when my book was announced as the winner, and it left me speechless at the moment!” says a modest Prof Snyman.

He adds: “I am sincerely grateful for this award, but I must also thank the university. I would like to express my appreciation for the academic milieu, financial support, as well as overseas travel opportunities that have enabled me to complete the book and achieve this award.”
 
Book review by international expert
Prof Rainer Kessler, a world-renowned expert on the Bible book of Malachi, said in a review of Malachi: “The commentary on Malachi in the renowned Historical Commentary on the Old Testament series is the fruit of decades of studies on the book. [It] is full of respect towards the text. [Prof] Snyman is very cautious in his judgements and decisions. He rather presents different possibilities than uttering one-sided positions. [Finally, he] treats others always in a very fair manner. He presents their opinions as objectively as possible, especially when he does not agree. This commentary is a new and very useful tool for the study on the often underestimated last book of the Old Testament prophets.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept